Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
7 September 2015

ORYZON achieves milestone in the clinical development of ORY-1001

2 March 2015

Dr. Carlos Buesa, Oryzon Genomics CEO, to be a Keynote Speaker at the 15th Annual Global Discovery-Summit 2015 in Lisbon, Portugal

20 July 2015

ORYZON Genomics to present at the 2015 Alzheimer's Association International Conference

12 November 2010

Oryzon Licenses Human Antibody Phage Display Technology for Discovery of Novel Therapeutics

1 March 2011

Oryzon to Present Recent Advances from its Project 'Innovative Approaches and Biomarkers in Parkinson Disease' at a Symposium in Barcelona

17 May 2011

Oryzon presents the results of the clinical study of GynEC-Dx: detection of endometrial cancer product

8 June 2011

Oryzon is present in the 76th Spanish National Congress of Urology

27 June 2011

Oryzon is present at the Bio International Convention of USA

6 July 2011

Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine

7 July 2011

Oryzon on the official program of the Euromediag International Convention (EIC 2011)

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Current page 49
  • Page 50
  • Page 51
  • Page 52
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel